Zuraiz Chaudhary
Known title: See RemarksCIK: 0002086494
Zuraiz Chaudhary's purchase track record
How the stock did after each of Zuraiz Chaudhary's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since October 23, 2025
Stock higher 6 months later
67%
3 months: 33%
Median 6-month return
+40.0%
3 months: -4.4%
Beat the S&P 500
67%
median +29.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/12/2025 | TTRX | $9K | +5.9% | +77.3% | +8.8% |
| 11/17/2025 | TTRX | $16K | -8.6% | +40.0% | +10.9% |
| 10/23/2025 | TTRX | $25K | -4.4% | -32.3% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TTRX | ▲ Buy | Open Market | 2,500 | $9K | 12/12/2025 | View on chart |
| TTRX | ▲ Buy | Open Market | 1,000 | $3K | 11/21/2025 | View on chart |
| TTRX | ▲ Buy | Open Market | 1,450 | $4K | 11/20/2025 | View on chart |
| TTRX | ▲ Buy | Open Market | 2,500 | $9K | 11/17/2025 | View on chart |
| TTRX | ▲ Buy | Open Market | 5,050 | $25K | 10/23/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Capital initiates coverage on TTRX with $24 target
Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.
Lucid Capital initiates coverage on TTRX with $24 target. Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.